Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Caux

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Science Signaling|February 18, 2016
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathwaySébastien Viel, Antoine Marçais, Fernando Souza-Fonseca Guimaraes, et al.
Cancer Immunology Research|January 8, 2025
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with MelanomaElisa Gobbini, Margaux Hubert, Anne-Claire Doffin, et al.
Bulletin Du Cancer|April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
Cancer Research|July 28, 2012
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progressionVanja Sisirak, Julien Faget, Michael Gobert, et al.
Oncoimmunology|July 4, 2012
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patientsManuarii Manuel, Olivier Tredan, Thomas Bachelot, et al.
Science Translational Medicine|January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancersAurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2014
Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cellsSreekumar Balan, Vincent Ollion, Nicholas Colletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trialLaetitia Collet, Maude Ardin, David Venet, et al.
Data in Brief|September 16, 2022
Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitorsJean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell CancerSara Santagata, Anna Maria Trotta, Crescenzo D'Alterio, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Science Signaling|February 18, 2016
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathwaySébastien Viel, Antoine Marçais, Fernando Souza-Fonseca Guimaraes, et al.
Cancer Immunology Research|January 8, 2025
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with MelanomaElisa Gobbini, Margaux Hubert, Anne-Claire Doffin, et al.
Bulletin Du Cancer|April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
Cancer Research|July 28, 2012
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progressionVanja Sisirak, Julien Faget, Michael Gobert, et al.
Oncoimmunology|July 4, 2012
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patientsManuarii Manuel, Olivier Tredan, Thomas Bachelot, et al.
Science Translational Medicine|January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancersAurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2014
Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cellsSreekumar Balan, Vincent Ollion, Nicholas Colletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trialLaetitia Collet, Maude Ardin, David Venet, et al.
Data in Brief|September 16, 2022
Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitorsJean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell CancerSara Santagata, Anna Maria Trotta, Crescenzo D'Alterio, et al.
Pageof 15